NBI-6024
NBI-6024, an altered peptide ligand (APL), is an epitope recognized by inflammatory interferon-gamma-producing T helper lymphocytes in type 1 diabetic patients.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 239480-61-6
- Formule: C106H180N28O34
- Masse moléculaire:2390.73
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nonobese diabetic (NOD) mice[2]
-
Dosage:0.005, 0.05, 0.5, 5, 10, 20 mg/kg
-
Administration:Subcutaneous injection (s.c.)
-
Result:Observed dose-dependent induction of responsiveness to the immunizing antigen at 5, 10, 20 mg/kg (tested by culturing spleen cells pooled from mice).
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 239480-61-6
-
Masse moléculaire 2390.73
-
Formule C106H180N28O34
-
Sequence Shortening
SHLVEALALVAGERG
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. D G Alleva et al. Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope. Scand J Immunol. 2006 Jan;63(1):59-69. [Content Brief]
[2]. Alleva DG, et al. Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes. 2002 Jul;51(7):2126-34. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)